RxDoctor Payments Data

Hong Chen

Physician Assistant · Brooklyn, NYNPI 1689921934

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (42.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Gilead at 39.5% of the total. Among physician assistant clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$56,511in general payments, 2019–2025

Across 871 payments — averaging $64.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$22K
  • Phathom Pharmaceuticals, Inc.$11K
  • IBSA Pharma Inc.$5K
  • AbbVie$3K
  • Amgen$3K
  • Esperion Therapeutics, Inc.$2K
  • plus $11K from 19 others

What the payments were for

  • Consulting fees$3,5256%
  • Speaking & faculty fees$23,74042%
  • Travel & lodging$5,70410%
  • Food & beverage$23,51642%
  • Education$250%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,511 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Epolamine1,019$937,575
Diclofenac Potassium225$451,574
VascepaIcosapent Ethyl819$404,962
VemlidyTenofovir Alafenamide173$254,304
JanuviaSitagliptin Phosphate163$148,884
RybelsusSemaglutide109$148,489
FarxigaDapagliflozin Propanediol161$146,003
ZenpepLipase/Protease/Amylase57$137,072
RestasisCyclosporine117$116,861
OtezlaApremilast18$88,999
ProliaDenosumab50$87,781
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate46$75,871
KerendiaFinerenone88$74,606
Dexlansoprazole DrDexlansoprazole293$72,034
JardianceEmpagliflozin73$68,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Linzess, Creon, Qulipta, Ubrelvy$2,851$288,510282 claims
GileadVemlidy$22,331$254,304173 claims
AstraZenecaFarxiga, Nexium, Breztri Aerosphere$1,258$221,422316 claims
AmgenOtezla, Prolia$2,645$176,78068 claims
Novo NordiskRybelsus$1,002$148,489109 claims
Aimmune Therapeutics, Inc.Zenpep$342$137,07257 claims
Boehringer IngelheimJardiance, Tradjenta$1,503$85,34393 claims
BayerKerendia$260$74,60688 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$2,321$59,414100 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$727$38,67653 claims
IBSA Pharma Inc.Licart$4,701$35,21742 claims
PfizerEliquis$387$28,37027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →